American Society of Hematology

American Society of Hematology Selects 31 Medical Students and Residents for 2017 HONORS Award

Published on: July 13, 2017

(WASHINGTON, July 13, 2017) – The American Society of Hematology (ASH) today announced the names of 18 medical students and 13 residents selected to receive the 2017 HONORS Award.

The ASH HONORS Award aims to support the career development of talented North American medical students and residents interested in hematology. Recipients receive a stipend of $5,000 to conduct hematology research projects either in the short-term (up to three months) or long-term (between three and 12 months) and $1,000 each year for two years to support their attendance at a program orientation at the ASH annual meeting. Each HONORS participant will have an ASH member research mentor who will assist and oversee the awardee’s work and progress.

“ASH is proud to support these talented hematologists early in their research careers,” said ASH President Kenneth C. Anderson, MD, of the Lebow Institute for Myeloma Therapeutics and Jerome Lipper Myeloma Center at Dana-Farber Cancer Institute in Boston. “We encourage these award recipients to continue research careers in hematology beyond medical school and residency and look forward to watching their careers develop.”

The 2017 ASH HONORS Award recipients are:

Medical Students:

RecipientsResearch Topics
Akshaya Arjunan, BS
UPMC Medical Education
Pittsburgh, PA 
Health care utilization and pain management before and after pediatric to adult transition of care in sickle cell disease
Allison Kirkpatrick, BA
University of Maryland
College Park, MD
MCL-1 reduction as a key molecular mechanism of the anti-leukemic activity of artemisinins
Andrew Simmerman, BM
Washington University/ Barnes-Jewish Hospital / St. Louis Children’s Hospital Consortium
St. Louis, MO
The role of DNA hypomethylation in acute myeloid leukemia mediated by DNMT3A loss

Ashley Paquin, BA
College of Medicine, Mayo Clinic
Rochester, MN

Survival and outcome of transplant-eligible patients with multiple myeloma

Calvin Harberg, BS
Medical College of Wisconsin Affiliated Hospitals
Milwaukee, WI

Reactive oxygen species as downstream signaling partners of CD36 in platelets
Charlotte Story, BS
University of North Carolina Hospitals
Chapel Hill, NC
Effect HLA phenotypes on long term graft-versus-host disease risk

Christopher Sande, BMus, BS, MMus
University of Iowa Hospitals and Clinics
Iowa City, IA 

Epidemiology & risk factors for inhibitor development in persons with hemophilia A: A national study
Colleen Flanagan, BA
University of Massachusetts
Worcester, MA
Evaluation of the immunogenicity of the mutant CALR C-terminus expressed in a majority of JAK2wt myeloproliferative neoplasms patients
Eamon Duffy, MD
Yale-New Haven Medical Center
New Haven, CT
The cell-mediated response to a novel influenza vaccine strategy in patients with plasma cell disorders
Erik Bao, BS
Boston Children's Hospital
Boston, MA
Dissecting the genetic architecture of human hematopoiesis
Jordan Spradbrow, BSc
Queen's University
Kingston, ON, Canada
Use of bleeding assessment tools in the diagnosis of von Willebrand disease: Are we asking the right questions?
Josiah To, MASc, BS
The Chicago Medical School at Rosalind Franklin University of Medicine and Science
North Chicago, IL 
Defining the impact of JAK2 V617F myeloproliferative neoplasms cells on their bone marrow stromal microenvironment
Kathryn Ivy, BA
Boston University School of Medicine
Boston, MA
Investigating the response to IDH1 inhibition in mutant IDH1 acute myeloid leukemia
Monica Chelius, BS
Dartmouth - Hitchcock Medical Center
Lebanon, NH
Very low dose radiotherapy for indolent lymphomas of the head/neck regions: predictors of response and assessment of toxicity
Nicholas Jackson Chornenki, BSc
McMaster University
Hamilton, ON, Canada
The real world practice of treating patients with polycythemia vera
Nikeshan Jeyakumar, MHS
University of Miami Miller School of Medicine
Miami, FL
Assessing the effect of ethnicity on CAR T-cell treatment outcomes
Phillip Staibano, BSc, MSc
University of Ottawa
Ottawa, ON, Canada
Usage of patient-centered outcomes in the management of anemia: A systematic review
Steven Hwang, BS
University of Michigan
Ann Arbor, MI
Role of polypyrimidine tract binding protein 1 in the oncogenesis of anaplastic large cell lymphoma

 

Residents:

RecipientsResearch Topics
Amrita Goyal, MD
University of Minnesota
Minneapolis, MN
Referral patterns and prognostic markers in mycosis fungoides
Andrea Cervi-Charron, MD, MSc
McMaster University
Hamilton, ON, Canada
Pharmacy hydroxyurea education materials for sickle cell disease: An environmental scan and assessment of accuracy
Anthony Sabulski, MD
Cincinnati Children's Hospital Medical Center
Cincinnati, OH
Fidelity of treatment response in a patient-derived xenograft leukemia avatar system
Cesar Gentille Sanchez, MD
Houston Methodist Hospital
Houston, TX
ESCAPEade. Incidence of antibiotic resistant infections and association with mortality in hematological malignancies
Chi-Joan How, MD
Washington University/B-JH/SLCH Consortium
St. Louis, MO
Prognostic significance of minimal residual disease in patients with secondary acute myeloid leukemia
Christina Abrams, BS, MD
University of Tennessee
Knoxville, TN
Abnormal FEF25-75% identifies asthma in sickle cell disease
Daniel Choi, MD
Albert Einstein College of Medicine
Bronx, NY
Hepatocyte growth factor/MET pathway inhibition in myeloproliferative neoplasms
Jessica El-Asmar, MD
Cleveland Clinic Foundation
Cleveland, OH
Prognosis and outcomes of adult acute myeloid leukemia in the contemporary era
Julia Xu, MD, MS
Duke University Hospital
Durhan NC
Thalassemia screening in migrants in Thailand
Katie McQueen, MD
Greenville Health System
Greenville, SC
Heart rate variability biofeedback: A patient-centered therapy for chronic pain and other symptoms of sickle cell disease
Maximilian Stahl, MD
Yale-New Haven Medical Center
New Haven, CT

The use of immunosuppressive treatment in patients with myelodysplastic syndrome: Outcomes and their clinical and molecular predictors in a large patient cohort
Nikita Baclig, MD, MPH
University of Washington
Seattle, WA
Retrospective analysis of outpatient management for adults with acute myeloid leukemia and myelodysplastic syndrome undergoing intensive (re-)induction chemotherapy
Yan Xu, BSc, MD
University of Toronto
Toronto, ON, Canada
Oral anticoagulant-related major bleeding definitions: comparison and assessment of significance

 


The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. ASH publishes Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online. In 2016, ASH launched Blood Advances (www.bloodadvances.org), an online, peer-reviewed open-access journal. 

CONTACT:
Sara Khalaf, American Society of Hematology
skhalaf@hematology.org; 202-552-4925

back to top